miR-125b Mediates Tau-induced Mitochondrial Dysfunction in a Cellular Model of Alzheimer’s Disease Authors: Laura De Plano, Alessandra Saitta, Aurelio Minuti, Claudia Muscarà, Irene Gasparo, Laura Licitri, Emanuele L. Sciuto, Sabrina Conoci, Giovanni Schepici, Antonella Caccamo, Francesca Polito, Salvatore Oddo, M.’hammed Aguennouz Published: 2026 ABSTRACT MicroRNA (miRNA) dysregulation contributes to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD), but the role of specific miRNAs in tau-mediated toxicity remains unclear. Here, we investigated the contribution of hsa-miR-125b to tau-induced cellular dysfunction using a stable neuronal cell line overexpressing mutant tau (P301L). We found that hsa-miR-125b levels were significantly elevated in tau-expressing cells compared to controls. Using bioinformatic tools, we identified a strong enrichment of predicted hsa-miR-125b targets involved in mitochondrial function. We validated several of these targets by RT-qPCR and confirmed the downregulation of mitochondrial-related transcripts, including genes encoding components of complexes I, IV, and V of the electron transport chain. To assess functional consequences, we performed Seahorse metabolic flux analysis and observed impaired mitochondrial respiration in tau-overexpressing cells, including reduced basal respiration, ATP production, and spare respiratory capacity. Our findings demonstrate that hsa-miR-125b contributes to tau-induced mitochondrial dysfunction by repressing transcripts essential for mitochondrial homeostasis. We propose that hsa-miR-125b acts as a mechanistic link between tau pathology and metabolic impairment in AD and may represent a promising target for therapeutic intervention.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12035-026-05982-x. Introduction Alzheimer’s disease (AD) is the most common form of age-related dementia, characterized by progressive memory loss and cognitive decline [1]. Neuropathologically, AD is defined by the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein [2]. Although Aβ pathology initiates early in the disease course, tau pathology correlates more strongly with synaptic loss and cognitive impairment [3]. In addition to its canonical role in microtubule stabilization, tau accumulation has been implicated in a range of cellular dysfunctions, including inflammation, oxidative stress, and mitochondrial impairment [4]. However, the molecular mediators linking tau pathology to these downstream effects remain poorly understood. MicroRNAs (miRNAs), a class of small non-coding RNAs that regulate gene expression by binding to complementary sequences on target mRNAs, have emerged as key regulators of neuronal development, plasticity, and stress responses [5, 6]. Among the miRNAs dysregulated in AD, hsa-miR-125b has garnered particular attention. Multiple studies have reported elevated hsa-miR-125b levels in the brains of AD patients, including the hippocampus and cortex, as well as in cerebrospinal fluid and blood-derived exosomes [7–9]. Mechanistically, hsa-miR-125b represses several genes critical for synaptic function, neurotrophic signaling, and mitochondrial homeostasis. For example, it downregulates synapsin-2 and 15-lipoxygenase (15-LOX), impairing membrane remodeling and reducing the production of neuroprotective docosanoids [8]. It also targets the anti-apoptotic gene Bcl-W, promoting tau-mediated apoptosis [9]. Overexpression of hsa-miR-125b in hippocampal neurons enhances tau phosphorylation via CDK5 activation, contributing to tangle formation [10, 11]. Multi-omics analyses have further linked hsa-miR-125b to the regulation of genes involved in mitochondrial metabolism and vesicular trafficking [12]. Mitochondrial dysfunction is a hallmark of both early and late stages of AD and contributes to synaptic failure, oxidative stress, and neuronal energy deficits [13]. Impairments in the electron transport chain, particularly in complexes I and IV, are consistently reported in AD brains [14]. Notably, tau has been shown to associate with mitochondrial membranes and inhibit its function [15]. Whether miRNAs such as hsa-miR-125b contribute to this mitochondrial dysfunction remains an open and compelling question. Notably, while several studies have established that hsa-miR-125b can act upstream of tau pathology by promoting tau phosphorylation and synaptic dysfunction, considerably less is known about whether tau itself can regulate hsa-miR-125b expression. This distinction is important, as it would imply the existence of a feed-forward regulatory loop in which tau pathology not only results from, but also reinforces, microRNA dysregulation. Moreover, although hsa-miR-125b has been broadly implicated in neuronal stress responses, its contribution to mitochondrial dysfunction in a tau-dependent context has not been directly assessed using integrated functional and transcriptional approaches. In this study, we sought to address this gap by investigating whether tau expression is associated with alterations in hsa-miR-125b levels and whether such changes contribute to mitochondrial dysfunction. To this end, we employed a cellular model stably overexpressing mutant tau (P301L). We found that hsa-miR-125b levels were significantly elevated in tau-expressing cells compared to controls. Bioinformatic analysis of predicted hsa-miR-125b targets revealed a strong enrichment for genes involved in mitochondrial function. RT-qPCR analysis confirmed the downregulation of several of these target genes. Furthermore, Seahorse metabolic flux analysis revealed impaired oxidative phosphorylation in tau-overexpressing cells. Collectively, these findings suggest a novel regulatory role for hsa-miR-125b in mediating tau-induced mitochondrial dysfunction. Our results provide insight into the post-transcriptional mechanisms that contribute to cellular pathology in AD and identify hsa-miR-125b not only as a potential biomarker, but also as a therapeutic target for restoring mitochondrial integrity in the diseased brain. Materials and Methods Cell Culture, Differentiation, and Transfection of SH-SY5Y and SH-Tau Cells SH-SY5Y human neuroblastoma cells and SH-SY5Y cells stably expressing the Tau-P301L mutant fused to tGFP (SH-Tau; Innoprot, Spain) were cultured in distinct media. SH-Tau cells have been previously characterized [16, 17]. SH-SY5Y cells were maintained in DMEM/F12 (Thermo Fisher Scientific, Waltham, MA) supplemented with 1% penicillin/streptomycin, while SH-Tau cells were cultured in RPMI-1640 medium supplemented with 0.3 mg/mL G418 for selection. For neuronal differentiation, both cell types were exposed to 10 μM retinoic acid (RA) (Labfor, Catania) and progressively decreasing concentrations of fetal bovine serum (FBS; Thermo Fisher Scientific). On day 0, cells were plated in their respective media containing 15% FBS. On day 1, the medium was replaced with fresh medium containing 2.5% FBS and 10 μM RA. On day 4, FBS was reduced to 1%, and on day 7, it was further lowered to 0.5%, with RA maintained throughout the experiments. To assess for a direct link between Tau and hsa-miRNA125b, cells were transfected with 1 μM hsa-miR-125b miRCURY LNA miRNA Inhibitor (Qiagen, Catalog number 339121) and processed for glycolytic and mitochondrial functional assays (see below). Neurite Length Quantification To assess neurite outgrowth, 20,000 cells per well were seeded into 8 wells (4 SH-SY5Y and 4 SH-Tau). Two images per well were captured at each differentiation time point. Neurite lengths were measured using the SNT plugin in ImageJ, with pixel-to-micron conversion based on a factor of 1 μm = 4.287525 pixels. Cell Viability Assay (MTT) At each differentiation stage, 7,000 cells/well were seeded into 96-well plates (10 wells per condition). At the end of each stage, viability was assessed by MTT assay (5 mg/mL; Sigma-Aldrich). After 2.5 h of incubation, the media was removed, and formazan crystals were dissolved in 100 μL of DMSO. Absorbance was measured at 540 nm using a microplate reader. RNA Isolation Total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany), following the manufacturer’s instructions. Cells were lysed in 350 μL RLT buffer supplemented with 20 μL/mL of 2 M dithiothreitol, vortexed, and mixed with 350 μL of 70% ethanol. The lysate was transferred to RNeasy spin columns and centrifuged at 8,000 × g for 15 s. Columns were washed with RW1 and twice with RPE buffer, and then centrifuged to dry the membrane. RNA was eluted in 35 μL RNase-free water. RNA purity and concentration were assessed with a NanoDrop spectrophotometer (Thermo Fisher Scientific). cDNA Synthesis from Mature miRNAs cDNA was synthesized from 45 ng of total RNA using the TaqMan™ Advanced miRNA cDNA Synthesis Kit (Thermo Fisher Scientific). The four-step protocol included:Polyadenylation of miRNAs at 37 °C for 45 minAdaptor ligation at the 5′ end at 16 °C for 60 minReverse transcription at 42 °C for 15 min followed by enzyme inactivation at 85 °C for 5 minPreamplification (miR-Amp): 95 °C for 10 min, then 14 cycles of 95 °C for 15 s and 60 °C for 4 min Polyadenylation of miRNAs at 37 °C for 45 min Polyadenylation of miRNAs at 37 °C for 45 min Adaptor ligation at the 5′ end at 16 °C for 60 min Adaptor ligation at the 5′ end at 16 °C for 60 min Reverse transcription at 42 °C for 15 min followed by enzyme inactivation at 85 °C for 5 min Reverse transcription at 42 °C for 15 min followed by enzyme inactivation at 85 °C for 5 min Preamplification (miR-Amp): 95 °C for 10 min, then 14 cycles of 95 °C for 15 s and 60 °C for 4 min Preamplification (miR-Amp): 95 °C for 10 min, then 14 cycles of 95 °C for 15 s and 60 °C for 4 min The resulting cDNA was diluted 1:10 and stored at –20 °C. Quantitative PCR was performed using TaqMan™ Advanced miRNA Assays specific for hsa-miR-125b-5p. Reverse Transcription of mRNA cDNA synthesis from mRNA was performed using the ImProm-II™ Reverse Transcription System (Promega). For each reaction, 1 μg of RNA and 0.5 μg of oligo(dT) primers were mixed in 5 μL, heated to 70 °C for 5 min, and cooled on ice. Then, 15 μL of RT master mix (buffer, MgCl₂, 10 mM dNTPs, 1 μL reverse transcriptase, and 1 μL RNasin® inhibitor) was added. The reaction was run at 25 °C for 5 min, 42 °C for 60 min, and 70 °C for 15 min. cDNA was stored at –20 °C. Quantitative Real-time PCR (qPCR) Gene expression was quantified using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad). Each 10 μL reaction contained 5 μL SYBR Green Supermix, 0.4 μL each of forward and reverse primers, 2 μL of cDNA, and nuclease-free water. Reactions were run in triplicate under the following conditions: 95 °C for 2 min, followed by 40 cycles of 95 °C for 3 s and 60 °C for 30 s. No-template controls (NTCs) were included for each primer set. Primer efficiency was verified (90–110%), and gene expression was calculated using the 2^–ΔΔCt method. GAPDH was used as the endogenous reference gene. Data are reported as mean ± standard deviation (SD) from at least six biological replicates. Statistical significance was assessed using a two-tailed unpaired Student’s t-test in GraphPad Prism; p < 0.05 was considered significant. Protein Extraction and Western Blot Total lysates from SH-SY5Y cells were obtained using a lysis buffer consisting of 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and both protease and phosphatase inhibitors. After removing the culture medium, cells were incubated with lysis buffer on ice for 20 min (40 µl per well), and then centrifuged for 30 min at 12,000 rpm at 4 °C. Following centrifugation, the supernatant was collected. Protein concentration was determined using a Nanodrop spectrophotometer. Western blot experiments were performed as previously described [18]. HT7 monoclonal antibody was purchased from Thermo Fisher Scientific and used at a dilution of 1:1000. β-Actin polyclonal antibody was purchased from Cell Signaling and used at a dilution of 1:5000. Bioinformatic Analysis of hsa-miR-125b-5p Target Genes Bioinformatic analysis was conducted using the DIANA-miPath v3.0 “reverse research” online platform (http://www.microrna.gr/miPathv3), which integrates both predicted and experimentally validated microRNA–mRNA interactions with KEGG pathway enrichment analysis. Within the platform, the KEGG pathway “Alzheimer’s disease” (hsa05010) was selected as the biological context. The species was set to Homo sapiens, and the microT-CDS algorithm was employed for target prediction, using the default interaction score threshold of 0.8 to balance sensitivity and specificity. This threshold filters for high-confidence miRNA–mRNA interactions based on sequence complementarity and evolutionary conservation. The analysis yielded a ranked list of microRNAs whose predicted or validated targets are significantly enriched in the AD pathway. From this list, hsa-miR-125b-5p was selected for further investigation. The mRNA sequences corresponding to hsa-miR-125b-5p Alzheimer’s-related target genes were retrieved from the NCBI Reference Sequence (RefSeq) database. Specific primers were designed using the Primer-BLAST tool, and their specificity was confirmed via BLAST alignment against the Homo sapiens transcriptome and genome. Only primer pairs with high specificity and no predicted off-target amplification were selected. The final primer sequences were synthesized by a commercial provider and used in quantitative real-time PCR to validate differential expression levels in the experimental samples. Glycolysis Function Assay Glycolytic function was assessed using the Seahorse XFe24 Extracellular Flux Analyzer (Agilent). SH-SY5Y and SH-Tau cells (7,000/well) were plated into Seahorse XF Cell Culture Microplates. One day before the assay, the Seahorse Sensor Cartridge was hydrated overnight in XF Calibrant at 37 °C in a non-CO₂ incubator. On the assay day, cells were treated for 3 h with 7.5 mM glucosamine or 25 mM glucose. The assay medium (XF DMEM, pH 7.4) was supplemented with 2 mM glutamine. Final compound concentrations were: 100 mM glucose, 10 mM oligomycin, and 500 mM 2-deoxyglucose (2-DG). Following a 1-h incubation in assay medium at 37 °C, cells were analyzed in the XFe24 Analyzer. Mitochondrial Function Assay Mitochondrial respiration was evaluated using the Agilent Seahorse XF Cell Mito Stress Test Kit, which measures oxygen consumption rate (OCR). SH-SY5Y and SH-Tau cells (7,000/well) were plated as described above. Cells were treated for 3 h with 7.5 mM glucosamine or 25 mM glucose. The assay medium (XF DMEM, pH 7.4) was supplemented with 2 mM glutamine, 10 mM glucose, and 1 mM pyruvate. Final drug concentrations were: 15 μM oligomycin, 10 μM FCCP, and 5 μM rotenone/antimycin A (Rot/AA). After a 1-h preincubation, OCR was recorded using the Seahorse XFe24 Analyzer. Results Tau Overexpression Induces Cytotoxicity and Morphological Changes in SH-SY5Y Cells To investigate the effects of mutant tau (P301L) on neuronal viability and morphology, we utilized SH-SY5Y human neuroblastoma cells stably transfected with tau P301L (hereafter referred to as SH-Tau), alongside untransfected SH-SY5Y controls (SH-CTL). Both cell lines were differentiated for 11 days using RA under serum-free conditions (Fig. 1A).Fig. 1Tau P301L overexpression induces cytotoxicity and alters cellular morphology in SH-SY5Y cells. (A) Schematic overview of the neuronal differentiation protocol used for SH-CTL and SH-Tau cells. (B) Cell viability of SH-CTL and SH-Tau cells was assessed over 7 days using the MTT assay. Data are presented as mean ± SD from three independent experiments, n = 12/genotype. A significant reduction in viability was observed in SH-Tau cells on day 7 (p < 0.001). Data were analyzed by One-way ANOVA Tau P301L overexpression induces cytotoxicity and alters cellular morphology in SH-SY5Y cells. (A) Schematic overview of the neuronal differentiation protocol used for SH-CTL and SH-Tau cells. (B) Cell viability of SH-CTL and SH-Tau cells was assessed over 7 days using the MTT assay. Data are presented as mean ± SD from three independent experiments, n = 12/genotype. A significant reduction in viability was observed in SH-Tau cells on day 7 (p < 0.001). Data were analyzed by One-way ANOVA We monitored cell viability throughout the differentiation process to capture the temporal dynamics of tau-induced cytotoxicity. Viability was comparable between SH-CTL and SH-Tau cells at early time points (days 1 and 4; p > 0.05; Fig. 1B). However, by day 7, SH-Tau cells exhibited a significant decrease in viability relative to controls (p < 0.001), marking a distinct window of tau-associated cytotoxicity. To further characterize tau-induced structural changes, we quantified neurite outgrowth over the 7-day differentiation period. SH-CTL cells exhibited a steady increase in neurite length, consistent with progressive neuronal maturation (Fig. 2A). In contrast, SH-Tau cells developed significantly shorter neurites at all examined time points (p < 0.0001), indicating persistent impairment of neuritic extension. We corroborated these structural alterations by morphological assessment using phase-contrast microscopy on day 7. SH-Tau cells displayed clear signs of cellular stress and degeneration, including rounded somas, reduced process complexity, and shortened neurites, in contrast to the healthier morphology of SH-CTL cells (Fig. 2B). These results indicate that tau P301L disrupts neurite outgrowth and maturation, contributing to both structural deficits and functional compromise during neuronal differentiation.Fig. 2Tau expression reduces neuritic outgrowth. (A) Quantification of neurite length over 7 days in SH-CTL and SH-Tau. Tau expression significantly reduced neurite length compared to controls, indicating impaired neuritic outgrowth. For Day 1, average neurite length was calculated from 38 SH-Tau and 66 SH-CTL neurites. For Day 4, measurements were obtained from 137 SH-Tau and 156 SH-CTL neurites. For Day 7, averages were based on 82 SH-Tau and 165 SH-CTL neurites. Data are shown as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. *p < 0.05; ***p < 0,001; ****p < 0.0001. (B) Representative phase-contrast images showing morphological differences between SH and SH-Tau cells at day 0 and day 7 Tau expression reduces neuritic outgrowth. (A) Quantification of neurite length over 7 days in SH-CTL and SH-Tau. Tau expression significantly reduced neurite length compared to controls, indicating impaired neuritic outgrowth. For Day 1, average neurite length was calculated from 38 SH-Tau and 66 SH-CTL neurites. For Day 4, measurements were obtained from 137 SH-Tau and 156 SH-CTL neurites. For Day 7, averages were based on 82 SH-Tau and 165 SH-CTL neurites. Data are shown as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. *p < 0.05; ***p < 0,001; ****p < 0.0001. (B) Representative phase-contrast images showing morphological differences between SH and SH-Tau cells at day 0 and day 7 Overexpression of Tau P301L Downregulates hsa-miR-125b Target Genes Involved in AD Pathways To investigate the molecular mechanisms underlying the tau-induced phenotype, we first confirmed the expression of mutant tau protein in our cellular model. Western blot analysis performed on day 7 revealed a prominent band corresponding to tau in SH-Tau cells, while no such band was detected in SH-CTL cells (Fig. 3A), confirming successful overexpression of the P301L mutant.Fig. 3hsa-miR-125b levels are increased in SH-Tau cells. (A) Western blot analysis confirming Tau P301L overexpression in SH-Tau cells (n = 5) compared to parental SH-SY5Y (SH-CTL) cells (n = 4). (B) Relative expression levels of hsa-miR-125b in SH-CTL and SH-Tau cells at day 7, measured by qRT-PCR and normalized by GAPDH. Hsa-miR-125b levels were significantly higher in SH-Tau cells, as indicated by lower Ct values, which indicate higher transcript abundance because fewer amplification cycles are required to reach the detection threshold. Statistical analysis was performed using an unpaired t-test; p < 0.05 hsa-miR-125b levels are increased in SH-Tau cells. (A) Western blot analysis confirming Tau P301L overexpression in SH-Tau cells (n = 5) compared to parental SH-SY5Y (SH-CTL) cells (n = 4). (B) Relative expression levels of hsa-miR-125b in SH-CTL and SH-Tau cells at day 7, measured by qRT-PCR and normalized by GAPDH. Hsa-miR-125b levels were significantly higher in SH-Tau cells, as indicated by lower Ct values, which indicate higher transcript abundance because fewer amplification cycles are required to reach the detection threshold. Statistical analysis was performed using an unpaired t-test; p < 0.05 Given the established role of microRNAs in AD pathogenesis, we focused on hsa-miR-125b, a brain-enriched microRNA that regulates tau phosphorylation, neurite outgrowth, and synaptic integrity [19]. To assess whether hsa-miR-125b might be implicated in the tau-induced phenotype observed in SH-Tau cells, we measured its expression levels on day 7, a time point when both cytotoxic and morphological changes were clearly evident. Quantitative PCR revealed a significant increase in hsa-miR-125b expression in SH-Tau cells compared to SH-CTL cells, as indicated by lower Ct values (Fig. 3B). This upregulation of hsa-miR-125b coincided with tau-induced toxicity and cellular disruption, suggesting that elevated hsa-miR-125b may contribute to the neurotoxic effects of mutant tau. To better understand the functional implications of increased hsa-miR-125b expression, we conducted a bioinformatic analysis using DIANA-miPath v3.0 in reverse search mode to identify putative mRNA targets of hsa-miR-125b. This analysis revealed nine predicted target genes significantly enriched in the AD pathway (Table 1). Functional annotation showed that these targets are involved in several biological processes implicated in AD, including mitochondrial respiration (NDUFS7, COX7A2L, COX7C, ATP5B, ATP5A1, ATP5G2, components of complexes I, IV, and V), synaptic signaling (GRIN2A, encoding the GluN2A subunit of the NMDA receptor), calcium signaling (ATP2A2, encoding SERCA2), and the amyloidogenic pathway (APP). Table 1Genes enriched in the Alzheimer’s disease pathway targeted by hsa-miR-125b and their known functions. The minimum free energy was calculated using RNAhybrid 2.2. Lower values correspond to stronger predicted interactionsGenes targeted byhas-miR-125bMinimum Free Energy (kcal/mol)Functional annotationAPP−25.9Amyloidogenic pathwayGRIN2A−26Synaptic signalingATP2A2−23.4Calcium signalingNDUFS7−49.29Mitochondrial respirationATP5A1−25.6Mitochondrial respirationCOX7C−15.9Mitochondrial respirationCOX7A2L−19Mitochondrial respirationATP5B−30.5Mitochondrial respirationATP5G2−28.6Mitochondrial respiration Table 1Genes enriched in the Alzheimer’s disease pathway targeted by hsa-miR-125b and their known functions. The minimum free energy was calculated using RNAhybrid 2.2. Lower values correspond to stronger predicted interactionsGenes targeted byhas-miR-125bMinimum Free Energy (kcal/mol)Functional annotationAPP−25.9Amyloidogenic pathwayGRIN2A−26Synaptic signalingATP2A2−23.4Calcium signalingNDUFS7−49.29Mitochondrial respirationATP5A1−25.6Mitochondrial respirationCOX7C−15.9Mitochondrial respirationCOX7A2L−19Mitochondrial respirationATP5B−30.5Mitochondrial respirationATP5G2−28.6Mitochondrial respiration Genes enriched in the Alzheimer’s disease pathway targeted by hsa-miR-125b and their known functions. The minimum free energy was calculated using RNAhybrid 2.2. Lower values correspond to stronger predicted interactions To validate the bioinformatics predictions, we randomly selected five of the nine genes for experimental verification using qRT-PCR in SH-Tau and SH-CTL cells. SH-Tau cells exhibited significant downregulation of mitochondrial genes ATP5G2 (Complex V; p < 0.01) and COX7C (Complex IV; p < 0.0005; Fig. 4A-B). NDUFS7 (Complex I) also showed a trend towards downregulation, although the difference did not reach statistical significance (p = 0.16; Fig. 4C). In addition, GRIN2A expression was significantly reduced in SH-Tau cells compared to SH-CTL (p < 0.01; Fig. 4D). This finding aligns with previous reports demonstrating that mutant tau impairs glutamatergic signaling, thereby contributing to synaptic dysfunction in AD [20]. Furthermore, ATP2A2 levels were markedly decreased in SH-Tau cells relative to controls (p < 0.001; Fig. 4E). Since SERCA2 plays a critical role in calcium reuptake and endoplasmic reticulum (ER) homeostasis, its downregulation may lead to ER stress and contribute to the neurodegenerative cascade observed in AD [21]. To validate the RT-PCR results, we measured the levels of ATP5G2 and NDUFS7 by western blot. Consistent with the RT-PCR data, the steady-state levels of ATP5G2 but not those of NDUFS7 were significantly lower in SH-Tau compared to SH cells (Fig. 4F-H). Future studies are needed to provide detailed mechanistic validation, including luciferase reporter assays and protein-level analyses.Fig. 4Quantitative real-time PCR and western blot analysis of gene expression in SH-SY5Y and SH-Tau cells. qRT-PCR was used to quantify the expression levels of (A) ATP5, (B) COX7, (C) NDUFS7, (D) GRIN2A, and (E) ATP2 in SH-CTL and SH-Tau cells. Gene expression was normalized to the housekeeping gene GAPDH using the ΔΔCt method. (F) Representative western blot probed with the indicated antibodies. (G-H) Quantitative analysis of the blots indicates that ATP5G2 levels were significantly lower in SH-Tau compared to SH-CTL cells. In contrast, the steady-state levels of NDUFS7 were similar between the two groups. Data are presented as mean ± SEM from six independent biological replicates and analyzed by an unpaired T-test. * p < 0.05; ** p = 0.0011; *** p = 0.0005 Quantitative real-time PCR and western blot analysis of gene expression in SH-SY5Y and SH-Tau cells. qRT-PCR was used to quantify the expression levels of (A) ATP5, (B) COX7, (C) NDUFS7, (D) GRIN2A, and (E) ATP2 in SH-CTL and SH-Tau cells. Gene expression was normalized to the housekeeping gene GAPDH using the ΔΔCt method. (F) Representative western blot probed with the indicated antibodies. (G-H) Quantitative analysis of the blots indicates that ATP5G2 levels were significantly lower in SH-Tau compared to SH-CTL cells. In contrast, the steady-state levels of NDUFS7 were similar between the two groups. Data are presented as mean ± SEM from six independent biological replicates and analyzed by an unpaired T-test. * p < 0.05; ** p = 0.0011; *** p = 0.0005 Together, these results suggest that tau P301L overexpression leads to increased expression of hsa-miR-125b, which in turn may disrupt multiple neuronal pathways, particularly those involving mitochondrial function, synaptic signaling, and calcium homeostasis, through repression of key target genes. Overexpression of Tau P301L Impairs Mitochondrial Function Our findings thus far indicate that overexpression of Tau P301L disrupts the expression of several genes involved in mitochondrial respiration, potentially compromising bioenergetic function and contributing to the neurodegenerative processes observed in tauopathies [22]. To test this hypothesis, we assessed mitochondrial function in SH-Tau and SH-CTL cells using a Seahorse XF Analyzer. We first measured the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), two key indicators of glycolytic and mitochondrial activity, respectively (Figs. 5 and 6). SH-CTL cells exhibited significantly higher ECAR and OCR values compared to SH-Tau cells, indicating more robust glycolytic and mitochondrial function in control cells (Figs. 5A-B, 6A-B).Fig. 5Glycolytic stress response in SH-CTL and SH-Tau cells. (A) Time-course profile of extracellular acidification rate (ECAR, mpH/min) in SH-CTL and SH-Tau cells following sequential injections of glucose, oligomycin, and 2-deoxy-D-glucose (2-DG). Cells were assessed for glycolytic function before and after treatment with 7.5 mM glucosamine or 25 mM glucose. (B) Agilent Seahorse XF Glycolysis Stress Test profile of the key parameters of glycolytic function. Sequential compound injections measure glycolysis, glycolytic capacity, and allow calculation of glycolytic reserve and non-glycolytic acidification. (C) Quantification of glycolytic parameters derived from ECAR traces. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison testFig. 6Mitochondrial stress response in SH-SY5Y and SH-Tau cells. (A) Time-course profile of oxygen consumption rate (OCR, pmol/min) in SH-CTL and SH-Tau cells following sequential injections of oligomycin, FCCP, and rotenone/antimycin A. Mitochondrial respiration was assessed before and after treatment with 7.5 mM glucosamine or 25 mM glucose. (B) Agilent Seahorse XF Cell Mito Stress Test profile, showing the injection sequence of modulators and the key parameters of mitochondrial function (basal respiration, ATP-linked respiration, maximal and reserve capacities, as well as non-mitochondrial respiration). (C) Quantification of maximal respiration based on the FCCP-stimulated OCR peak. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test Glycolytic stress response in SH-CTL and SH-Tau cells. (A) Time-course profile of extracellular acidification rate (ECAR, mpH/min) in SH-CTL and SH-Tau cells following sequential injections of glucose, oligomycin, and 2-deoxy-D-glucose (2-DG). Cells were assessed for glycolytic function before and after treatment with 7.5 mM glucosamine or 25 mM glucose. (B) Agilent Seahorse XF Glycolysis Stress Test profile of the key parameters of glycolytic function. Sequential compound injections measure glycolysis, glycolytic capacity, and allow calculation of glycolytic reserve and non-glycolytic acidification. (C) Quantification of glycolytic parameters derived from ECAR traces. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test Mitochondrial stress response in SH-SY5Y and SH-Tau cells. (A) Time-course profile of oxygen consumption rate (OCR, pmol/min) in SH-CTL and SH-Tau cells following sequential injections of oligomycin, FCCP, and rotenone/antimycin A. Mitochondrial respiration was assessed before and after treatment with 7.5 mM glucosamine or 25 mM glucose. (B) Agilent Seahorse XF Cell Mito Stress Test profile, showing the injection sequence of modulators and the key parameters of mitochondrial function (basal respiration, ATP-linked respiration, maximal and reserve capacities, as well as non-mitochondrial respiration). (C) Quantification of maximal respiration based on the FCCP-stimulated OCR peak. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test To further explore the metabolic response of the cells, we treated both lines with either glucose or glucosamine, a known metabolic inhibitor. In SH-CTL cells, glucosamine treatment led to a significant decrease in ECAR, confirming suppression of glycolytic activity (Fig. 6A, C). Mitochondrial function was similarly affected, as indicated by reductions in OCR and related parameters, including maximal respiration (Fig. 5A-B). In contrast, SH-Tau cells did not show any significant changes in ECAR or OCR upon treatment with glucose or glucosamine. Notably, glucose failed to enhance either glycolytic or mitochondrial activity in SH-Tau cells, possibly due to high-glucose-induced inhibition of mitochondrial electron transport and ATP synthesis. These results support the notion that SH-Tau cells have a diminished capacity to modulate mitochondrial metabolism in response to energetic stress. To further understand the relation between Tau and glycolytic stress, we transfected SH-Tau and SH-CTL cells with an hsa-miR-125b inhibitor. While inhibiting hsa-miR-125b did not alter mitochondrial respiration (Supplementary Fig. 3), it significantly improved glycolytic stress response (Fig. 7). Taken together, these findings suggest that Tau P301L overexpression leads to mitochondrial dysfunction. This deficit is partially mediated by hsa-miR-125b-dependent downregulation of key genes involved in oxidative phosphorylation. This impairment in mitochondrial respiration may contribute to the energy deficits and cellular stress observed in tauopathies.Fig. 7Glycolytic stress response in SH-CTL and SH-Tau cells after hsa-miR-125b inhibition. (A) Time-course profile of the extracellular acidification rate (ECAR, mpH/min) in SH-SY5Y and SH-Tau cells treated with a hsa-miR-125b Inhibitor and subjected to sequential injections of glucose, oligomycin and 2-deoxy-D-glucose (2DG) to assess glycolytic activity pre- and post-treatments with 7.5 mM glucosamine or 25 mM glucose. (B) Agilent Seahorse XF Glycolysis Stress Test profile of the key parameters of glycolytic function. Sequential compound injections measure glycolysis, glycolytic capacity, and allow calculation of glycolytic reserve and non-glycolytic acidification. (C) Quantification of glycolytic parameters derived from ECAR trace. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01, #p < 0.05 Glycolytic stress response in SH-CTL and SH-Tau cells after hsa-miR-125b inhibition. (A) Time-course profile of the extracellular acidification rate (ECAR, mpH/min) in SH-SY5Y and SH-Tau cells treated with a hsa-miR-125b Inhibitor and subjected to sequential injections of glucose, oligomycin and 2-deoxy-D-glucose (2DG) to assess glycolytic activity pre- and post-treatments with 7.5 mM glucosamine or 25 mM glucose. (B) Agilent Seahorse XF Glycolysis Stress Test profile of the key parameters of glycolytic function. Sequential compound injections measure glycolysis, glycolytic capacity, and allow calculation of glycolytic reserve and non-glycolytic acidification. (C) Quantification of glycolytic parameters derived from ECAR trace. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01, #p < 0.05 Discussion Our study demonstrates that overexpression of tau harboring the P301L mutation in differentiated SH-SY5Y cells leads to pronounced cytotoxicity, neuritic degeneration, and profound molecular alterations, including the dysregulation of microRNA signaling and mitochondrial dysfunction. These findings provide mechanistic insights into how tau pathology can disrupt neuronal integrity and function through hsa-miR-125b-mediated repression of genes essential for bioenergetic homeostasis, synaptic signaling, and calcium handling. We observed that the cytotoxic effects of tau P301L were temporally dynamic, peaking at day 7 of differentiation and coinciding with clear morphological abnormalities. This transient window of maximal toxicity is consistent with prior studies showing that tau-induced stress can trigger compensatory survival responses or selective death of the most vulnerable neuronal populations [23, 24]. Morphologically, SH-Tau cells exhibited shortened neurites and reduced arborization, confirming previous reports in both in vitro and in vivo models of tauopathy [25, 26]. The impairment in neurite outgrowth observed throughout the differentiation process suggests that tau P301L compromises cytoskeletal dynamics or axonal transport, both hallmarks of tau-induced neurodegeneration [27, 28]. Previous studies have established that hsa-miR-125b can modulate tau phosphorylation, synaptic integrity, and neuronal stress responses, positioning this microRNA primarily as an upstream regulator of tau pathology [10, 19]. While these reports support a role for hsa-miR-125b upstream of tau dysregulation, they do not address whether tau itself can influence hsa-miR-125b expression. Here, we provide compelling evidence that expression of TauP301L is sufficient to increase endogenous hsa-miR-125b levels, revealing a previously unrecognized feed-forward regulatory loop that may amplify neuronal dysfunction. In addition, whereas the earlier studies did not directly assess mitochondrial parameters, our data show that dysregulation of hsa-miR-125b is associated with measurable impairments in mitochondrial respiration and metabolic capacity. Together, these observations extend current understanding by linking tau-induced hsa-miR-125b upregulation to mitochondrial dysfunction, a key contributor to neuronal vulnerability in AD and related tauopathies. This expanded mechanistic framework suggests that targeting hsa-miR-125b may provide a means to interrupt deleterious feed-forward processes that exacerbate neuronal injury. While our data demonstrate a clear association between tau expression, increased hsa-miR-125b levels, and mitochondrial dysfunction, it is important to interpret these findings within the context of the experimental model used. The SH-Tau cell line differs from the control only by the stable expression of mutant tau (P301L), and therefore all observed phenotypic differences arise as direct or indirect consequences of tau expression. However, this approach does not allow us to formally distinguish whether tau directly regulates hsa-miR-125b or whether this effect is mediated through intermediate stress-response pathways. Thus, our findings support a model in which tau expression is sufficient to drive hsa-miR-125b upregulation and downstream mitochondrial alterations, rather than establishing a direct mechanistic interaction. Future studies employing complementary approaches, such as tau knockdown or inducible systems, will be important to further dissect the upstream regulatory mechanisms governing hsa-miR-125b expression. Importantly, the data presented here implicate hsa-miR-125b as a potential mediator of tau-induced neurotoxicity. hsa-miR-125b is a brain-enriched microRNA previously reported to regulate tau phosphorylation, neurite morphology, and synaptic maintenance [10, 19]. Its upregulation in SH-Tau cells suggests that tau pathology may drive transcriptional or post-transcriptional changes in microRNA expression, possibly through feedback mechanisms involving cellular stress or inflammatory signaling [10, 29]. The fact that increased hsa-miR-125b expression coincides with peak cytotoxicity strengthens the hypothesis that this microRNA contributes to the degenerative cascade initiated by mutant tau. Our bioinformatic and experimental analyses revealed that hsa-miR-125b targets several mRNAs involved in AD-related pathways. Of particular interest are genes encoding components of mitochondrial complexes I, IV, and V (e.g., NDUFS7, COX7C, ATP5G2), the NMDA receptor subunit GRIN2A, and the ER calcium ATPase ATP2A2 (SERCA2). Downregulation of these targets in SH-Tau cells suggests that has-miR-125b contributes to widespread functional impairments. For example, the suppression of GRIN2A is likely to disrupt glutamatergic signaling and synaptic plasticity, processes already known to be vulnerable in early AD stages [30–32]. Likewise, repression of ATP2A2 may impair calcium reuptake into the ER, promoting ER stress and calcium dyshomeostasis, both of which are implicated in neuronal dysfunction and cell death in AD [29, 33, 34]. A particularly striking finding of our study is the bioenergetic deficit observed in SH-Tau cells. Seahorse metabolic analysis showed reduced glycolytic and mitochondrial activity, as evidenced by lower ECAR and OCR values. Notably, SH-Tau cells failed to respond to metabolic stressors such as glucose or glucosamine, indicating an inability to adapt mitochondrial respiration to changing energetic demands. These defects align with the observed downregulation of oxidative phosphorylation genes and suggest that tau pathology induces a rigid, metabolically inflexible state. Mitochondrial dysfunction is a well-established feature of AD pathology and has been linked to both Aβ and tau accumulation [35, 36]. Our results extend this view by proposing a regulatory axis (mutant tau to hsa-miR-125b to mitochondrial gene repression) that contributes to impaired oxidative phosphorylation and neuronal vulnerability. The mitochondrial impairments observed may also further exacerbate tau pathology. Reduced ATP levels can compromise kinase/phosphatase balance, affect tau phosphorylation status, and impair proteostasis, potentially accelerating the aggregation of toxic tau species [35, 37]. Furthermore, mitochondrial deficits may generate reactive oxygen species, which can further damage neuronal membranes, DNA, and proteins, amplifying the neurodegenerative cascade [38, 39]. While further studies are warranted to dissect the upstream signals that drive hsa-miR-125b elevation in tauopathy, collectively, our data suggest a novel mechanism by which tau P301L induces neuronal dysfunction via upregulation of hsa-miR-125b and subsequent repression of genes critical for neuronal metabolism and signaling. These findings support the growing view that tau pathology extends beyond microtubule destabilization and includes complex regulatory interactions with RNA networks and metabolic pathways. Targeting hsa-miR-125b or restoring the expression of its key targets may offer promising therapeutic avenues for mitigating tau-induced neurodegeneration. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 846 KB) Supplementary file1 (DOCX 846 KB)